Provides esoteric testing services to hospitals in China. Offers diagnostic solutions for hematologic tumors and rare diseases. Now — the numbers.
We do not hold enough financial data on this company to point to a strength.
The stock sits at $0.68. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The price action doesn’t yet back an upward turn.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown, the price history.